Stock A263050 EUTILEX.CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Eutilex.Co.,Ltd

Equities

A263050

KR7263050007

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 20/06/2024 BST 		5-day change 1st Jan Change
1,906 KRW -0.26% Intraday chart for Eutilex.Co.,Ltd -4.70% -43.61%
05-16 Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-21 Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Eutilex.Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Eutilex.Co.,Ltd(KOSDAQ:A263050) dropped from S&P Global BMI Index
CI
Eutilex.Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Eutilex.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Eutilex.Co.,Ltd. announced that it has received KRW 22.5003376 billion in funding
CI
Eutilex.Co.,Ltd. announced that it expects to receive KRW 22.5003376 billion in funding
CI
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
CI
Eutilex.Co.,Ltd. announced that it has received KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One
CI
Eutilex.Co.,Ltd. announced that it expects to receive KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One
CI
Eutilex Co.,Ltd. announced that it has received KRW 29 billion in funding
CI
Eutilex Co.,Ltd. announced that it expects to receive KRW 29 billion in funding
CI
CDMO business GenScript ProBio and Eutilex Co., Ltd. Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for Car-T Programs
CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index
CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index
CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index
CI
Eutilex Co.,Ltd. has completed an IPO in the amount of KRW 36.35 billion.
CI
Eutilex Co.,Ltd. has filed an IPO.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A263050 Stock
  4. News Eutilex.Co.,Ltd